Contineum Therapeutics, Inc. Research and Development Expense
Contineum Therapeutics, Inc. (CTNM) reported Research and Development Expense of $12.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- Contineum Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $12.70M, a 9.68% decline year-over-year.
- Contineum Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $11.65M, a 15.05% decline year-over-year.
- Contineum Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $12.76M, a 2.00% decline year-over-year.
- Contineum Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $10.99M, a 12.99% increase year-over-year.
- Contineum Therapeutics, Inc. research and development expense for fiscal 2025 was $51.52M, a 34.10% increase from fiscal 2024.
- Contineum Therapeutics, Inc. research and development expense for fiscal 2024 was $38.42M, a 39.20% increase from fiscal 2023.
- Contineum Therapeutics, Inc. research and development expense for fiscal 2023 was $27.60M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.70M 10-Q · filed 2026-07-30 | $24.35M 10-Q · filed 2026-07-30 | $37.10M derived: sum of 3 quarters · filed 2026-07-30 | $48.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $11.65M 10-Q · filed 2026-05-05 | $24.40M derived: sum of 2 quarters · filed 2026-05-05 | $35.40M derived: sum of 3 quarters · filed 2026-05-05 | $49.46M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $12.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $23.75M derived: sum of 2 quarters · filed 2026-03-05 | $37.81M derived: sum of 3 quarters · filed 2026-07-30 | $51.52M 10-K · filed 2026-03-05 |
| 2025-09-30 | $10.99M 10-Q · filed 2025-10-30 | $25.05M derived: sum of 2 quarters · filed 2026-07-30 | $38.77M 10-Q · filed 2025-10-30 | $51.78M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $14.06M 10-Q · filed 2026-07-30 | $27.77M 10-Q · filed 2026-07-30 | $40.79M derived: sum of 3 quarters · filed 2026-07-30 | $50.52M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $13.71M 10-Q · filed 2026-05-05 | $26.73M derived: sum of 2 quarters · filed 2026-05-05 | $36.45M derived: sum of 3 quarters · filed 2026-05-05 | $44.36M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $13.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $22.74M derived: sum of 2 quarters · filed 2026-03-05 | $30.64M derived: sum of 3 quarters · filed 2026-03-05 | $38.42M 10-K · filed 2026-03-05 |
| 2024-09-30 | $9.73M 10-Q · filed 2025-10-30 | $17.63M derived: sum of 2 quarters · filed 2025-10-30 | $25.41M 10-Q · filed 2025-10-30 | $33.42M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $7.90M 10-Q · filed 2025-08-05 | $15.68M 10-Q · filed 2025-08-05 | $23.69M derived: sum of 3 quarters · filed 2025-08-05 | $30.19M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $7.78M 10-Q · filed 2025-05-14 | $15.79M derived: sum of 2 quarters · filed 2025-05-14 | $22.29M derived: sum of 3 quarters · filed 2025-05-14 | $31.75M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $8.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $14.51M derived: sum of 2 quarters · filed 2025-03-06 | $23.97M derived: sum of 3 quarters · filed 2025-03-06 | $27.60M 10-K · filed 2025-03-06 |
| 2023-09-30 | $6.50M 10-Q · filed 2024-11-06 | $15.96M derived: sum of 2 quarters · filed 2024-11-06 | $19.59M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $9.46M 10-Q · filed 2024-08-14 | $13.09M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $3.63M 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |